Montelukast Cinfa (Montelukast Sodium)

Montelukast Sodium works by selectively blocking the cysteinyl leukotriene receptor CysLT1. By preventing leukotriene D4 from binding, it stops the cascade that leads to bronchoconstriction, mucus production, and inflammatory cell recruitment, thereby easing airway and nasal passage inflammation.

The specific dose of Montelukast Cinfa is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Clinicians follow approved dosing guidelines, but the exact regimen should always be individualized and confirmed by the prescriber.

Safety data for Montelukast Cinfa in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the Montelukast Cinfa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any special handling) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or other leukotriene blockers such as zafirlukast. Compared with inhaled steroids, Montelukast provides systemic coverage without the need for inhalation devices, though it may be less potent for acute symptom relief. It is often used as add‑on therapy or when inhaled options are unsuitable.

Montelukast Cinfa should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat, and direct sunlight. Do not store in a bathroom or near a kitchen sink where humidity is high.

Montelukast Cinfa is taken orally, usually as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include neuropsychiatric events such as depression, suicidal thoughts, or mood changes, as well as severe allergic reactions like angioedema, anaphylaxis, and rare skin conditions such as Stevens‑Johnson syndrome. Any sudden or severe symptoms should prompt immediate medical evaluation.

Montelukast Cinfa should be avoided in individuals with known hypersensitivity to Montelukast Sodium or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment or those taking interacting medications that could significantly alter drug levels.